Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

Background: HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents. Methods: 54 HER2+ MBC patients treated with HER2 targeted therapy as first line treatment were ana...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Biol Ther
Autori principali: Omarini, Claudia, Bettelli, Stefania, Caprera, Cecilia, Manfredini, Samantha, Caggia, Federica, Guaitoli, Giorgia, Moscetti, Luca, Toss, Angela, Cortesi, Laura, Kaleci, Shaniko, Maiorana, Antonino, Cascinu, Stefano, Conte, Pier Franco, Piacentini, Federico
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300343/
https://ncbi.nlm.nih.gov/pubmed/30067438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480287
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi